Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma

Elotuzumab (Elo) is an IgG(1) monoclonal antibody targeting SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) cells, natural killer (NK) cells, and subsets of other leukocytes. By engaging with FcγRIIIA (CD16), Elo promotes potent NK cell–mediated antibody-dependent cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Pazina, Tatiana, James, Ashley M., Colby, Kimberly B., Yang, Yibin, Gale, Andrew, Jhatakia, Amy, Kearney, Alper Y., Graziano, Robert F., Bezman, Natalie A., Robbins, Michael D., Cohen, Adam D., Campbell, Kerry S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774869/
https://ncbi.nlm.nih.gov/pubmed/31431433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados